[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Argent Biopharma Limited (RGT.LN)

Argent Biopharma Limited (RGT.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Argent Biopharma Limited 295 Rokeby Road Suite 1 Subiaco WA 6008 AUS

https://www.argentbiopharma.com P: +61 865552950 F: +61 861660261

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.

Key Statistics

Overview:

Market Capitalization, $K 4,178
Shares Outstanding, K 54,272
% of Institutional Shareholders 0.38%

Financials:

Annual Sales, $ 583 K
Annual Net Income, $ -17,844 K

Growth:

1-Year Return -71.43%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth -22.44%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm -0.47
Dividend Payout Ratio 0.00%
Most Recent Split 1-1000 on 11/02/23

RGT.LN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Return-on-Equity % N/A
Return-on-Assets % -340.00%
Profit Margin % -3,058.43%
Debt/Equity N/A
Price/Sales 5.44
Price/Book N/A
Book Value/Share -0.05
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.